Rheumatology Advance Access published online on June 1, 2004
Rheumatology, doi:10.1093/rheumatology/keh229
Rheumatology © British Society for Rheumatology 2004; all rights reserved
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Divisions of Clinical Immunology and Allergy, McGill University, Montréal, Québec, Canada; Division of Clinical Epidemiology, Department of Medicine McGill University Health Centre, McGill University, Montréal, Québec, Canada
* To whom correspondence should be addressed. E-mail: ann.clarke{at}mcgill.ca.
Objective. Health consumption and health status in SLE in three countries with different health funding structures were compared. Methods. Seven hundred and fifteen SLE patients (Canada 231, USA 269, UK 215) were surveyed semi-annually over 4 yr for health resource utilization and health status. Cross-country comparisons of (i) cumulative health expenditure (calculated by applying 2002 Canadian prices to resources in all countries) and (ii) disease damage (Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index, SLICC/ACR DI) at study conclusion were performed after adjustment. Missing expenditure and damage data were managed through multiple imputation using best predictive regressions with all available data from all patients as potential covariates. Results. Four hundred and eighty-five patients provided data at study entry and conclusion and at least four resource questionnaires (Canada 162, USA 157, UK 166); 41 died (Canada 13, USA 18, UK 10); 189 withdrew, were lost to follow-up or provided data at entry and conclusion but fewer than four resource questionnaires (Canada 56, USA 94, UK 39). At conclusion, after imputation, in Canada, the USA and the UK respectively, mean cumulative costs per patient over 4 yr [95% confidence interval (CI)] were \$15 845 (13 509, 18 182), \$20 244 (17 764, 22 724) and \$17 647 (15 557, 19 737) and mean changes in SLICC/ACR DI were 0.49 (0.39, 0.60), 0.63 (0.52, 0.74) and 0.48 (0.39, 0.57). After adjustment for baseline differences, on average (95% CI), Canadian and British patients utilized 20% (8%, 32%) and 13% (1%, 24%) less resources than patients in the USA respectively, but experienced similar health outcomes. Conclusion. Despite patients in the USA incurring higher health expenditures, they did not experience superior health outcomes. KEY WORDS:
Systemic lupus erythematosus, Economics, Disease damage, SLICC damage index, Direct health care costs.
Accepted April 8, 2004
Original Papers
The systemic lupus erythematosus Tri-nation Study: absence of a link between health resource use and health outcome
2 Department of Medicine (Division of Rheumatology), Johns Hopkins University School of Medicine, Baltimore, MD, USA
3 Department of Medicine (Division of Rheumatology) and Department of Epidemiology, University of Pittsburgh, Pittsburgh, PA, USA
4 Centre for Rheumatology, Department of Medicine, University College London, London, UK
5 Department of Rheumatology, University of Birmingham, Birmingham, UK
6 Department of Medicine (Division of Rheumatology), Hôpital Notre-Dame, Université de Montréal, Montréal, Québec, Canada
7 Department of Clinical Epidemiology, Department of Medicine McGill University Health Centre, McGill University, Montréal, Québec, Canada; Department of Economics, McGill University, Montréal, Québec, Canada
8 Division of Clinical Epidemiology, Department of Medicine McGill University Health Centre, McGill University, Montréal, Québec, Canada; Departments of Epidemiology and Biostatistics, McGill University, Montréal, Québec, Canada
9 Division of Clinical Epidemiology, Department of Medicine McGill University Health Centre, McGill University, Montréal, Québec, Canada
10 Department of Medicine (Division of Rheumatology) and Department of Epidemiology, University of Toronto, Toronto, Ontario, Canada
11 Arthritis Research Centre of Canada and Department of Medicine, University of British Columbia, Vancouver, BC, Canada
Abstract 
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  T. Y. Zhu, L.-S. Tam, V. W. Y. Lee, K. K. Lee, and E. K. Li Systemic lupus erythematosus with neuropsychiatric manifestation incurs high disease costs: a cost-of-illness study in Hong Kong Rheumatology, May 1, 2009; 48(5): 564 - 568. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C Gordon, G Bertsias, J P A Ioannidis, J Boletis, S Bombardieri, R Cervera, C Dostal, J Font, I-M Gilboe, F Houssiau, et al. EULAR points to consider for conducting clinical trials in systemic lupus erythematosus Ann Rheum Dis, April 1, 2009; 68(4): 470 - 476. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. E. Clarke, P. Panopalis, M. Petri, S. Manzi, D. A. Isenberg, C. Gordon, J.-L. Senecal, L. Joseph, Y. St Pierre, and T. Li SLE patients with renal damage incur higher health care costs Rheumatology, March 1, 2008; 47(3): 329 - 333. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Callaghan, A. Prabu, R. B. Allan, A. E. Clarke, N. Sutcliffe, Y. St. Pierre, C. Gordon, S. J. Bowman, and the UK Sjogren's Interest Group Direct healthcare costs and predictors of costs in patients with primary Sjogren's syndrome Rheumatology, January 1, 2007; 46(1): 105 - 111. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E D Hale, G J Treharne, A C Lyons, Y Norton, S Mole, D L Mitton, K M J Douglas, N Erb, and G D Kitas "Joining the dots" for patients with systemic lupus erythematosus: personal perspectives of health care from a qualitative study Ann Rheum Dis, May 1, 2006; 65(5): 585 - 589. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Panopalis, M. Petri, S. Manzi, D. A. Isenberg, C. Gordon, J.-L. Senecal, J. R. Penrod, L. Joseph, Y. St. Pierre, C. Pineau, et al. The systemic lupus erythematosus tri-nation study: longitudinal changes in physical and mental well-being Rheumatology, June 1, 2005; 44(6): 751 - 755. [Abstract] [Full Text] [PDF]
|
|